Regorafenib 40 MG Oral Tablet

DRUG2 trials

Sponsors

Universitair Ziekenhuis Brussel, Istituto Oncologico Veneto IRCCS

Conditions

Melanoma Stage IIIMelanoma Stage IVMeningioma, Malignant

Phase 2

A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma

Active, not recruitingNCT05370807

Universitair Ziekenhuis BrusselMelanoma Stage III, Melanoma Stage IV

Start: 2022-10-03End: 2027-03-01Target: 48Updated: 2026-09-30

Regorafenib for Recurrent Meningioma (MIRAGE Trial)

RecruitingNCT06275919

Istituto Oncologico Veneto IRCCSMeningioma, Malignant

Start: 2024-09-23End: 2029-03-01Target: 104Updated: 2026-09-30

Related Papers

TIP-05. Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: the MIRAGE trial

Neuro-Oncology2025-11-01

P13.14.A REGORAFENIB VERSUS LOCAL STANDARD OF CARE IN PATIENTS WITH GRADE 2-3 MENINGIOMA NO LONGER ELIGIBLE FOR LOCO-REGIONAL TREATMENTS: THE MIRAGE TRIAL

Neuro-Oncology2025-10-01

Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study).

2025-08-04

Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: The MIRAGE trial.

Journal of Clinical Oncology2025-05-28

A phase 2 clinical trial of regorafenib in patients with advanced pretreated melanoma (RegoMel).

Journal of Clinical Oncology2024-06-01